enGene Therapeutics Inc. (ENGN) › Operating IncomeenGene Therapeutics Inc. (ENGN) — Operating IncomeAnnual figures by period end, from SEC filings.2022-10-31: -$19.43M2023-10-31: -$26.06M2024-10-31: -$62.30M2025-10-31: -$123.17M-$123.17M2022-10-31Operating Income (USD)2025-10-31Period endedOperating IncomeChange YoYSource filing2025-10-31-$123.17M—2025-12-22From 2024-11-012024-10-31-$62.30M—2025-12-22From 2023-11-012023-10-31-$26.06M—2024-12-19From 2022-11-012022-10-31-$19.43M—2024-01-29From 2021-11-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)